Loading...
XNAS
VRDN
Market cap1.82bUSD
Jul 09, Last price  
20.20USD
1D
1.71%
1Q
35.12%
Jan 2017
-73.12%
IPO
-98.94%
Name

Viridian Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:VRDN chart
P/E
—
P/S
25.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
88.57%
Rev. gr., 5y
132.18%
Revenues
71m
+23,359.93%
4,406,0424,316,4844,320,0002,538,0003,337,0004,003,0008,386,0004,461,0001,050,0002,963,0001,772,000314,000302,00070,849,000
Net income
-343m
L+26.91%
-7,211,285-2,159,669-7,890,000-11,328,000-12,674,000-26,512,000-32,703,000-41,873,000-110,715,000-79,413,000-129,874,000-237,734,000-269,949,000-342,601,000
CFO
-276m
L+18.97%
-6,224,802-1,167,793-2,213,000-6,898,000-7,231,000-28,167,000-26,844,000-36,056,000-29,779,000-54,581,000-93,838,000-184,170,000-232,319,000-276,391,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
URL
https://www.viridiantherapeutics.com/
IPO date
Jun 18, 2014
Employees
86
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT